Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Go back to Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis| (NYSE: NSRX) | Delayed: 3.53 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.53 | 52 Week High | $ | |||
| Open | $3.35 | 52 Week Low | $ | |||
| Day High | $3.58 | P/E | N/A | |||
| Day Low | $3.35 | EPS | $ | |||
| Volume | 12,021 | |||||
